An extraordinary general meeting in
Approval of merger plan
The extraordinary general meeting resolved, by required majority, to approve the merger plan adopted by the board of directors of
The merger is expected to be registered with the Swedish Companies Registration Office in the first quarter 2020 and will result in the dissolution of Karessa, whereby all of Karessas's assets and liabilities will be transferred to Klaria. Settlement of the merger consideration will take place following the Swedish Companies Registration Office's registration of the merger.
This is information that
For more information, please contact:
Mats Nilsson,
Tel: +46-8-768 22 33
mats.nilsson@karessa.se
About
Karessa is a Swedish pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. For more information, visit karessa.se. Certified Advisor:
https://news.cision.com/karessa-pharma-holding-ab/r/extraordinary-general-meeting-in-karessa-pharma-on-18-december-2019,c2994130
https://mb.cision.com/Main/11036/2994130/1163939.pdf
(c) 2019 Cision. All rights reserved., source